Marta Budzinska - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Marta Budzinska's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Marta Budzinska
Verified
Medical Writer, Avalere Health
High Wycombe, London
Beats
Biotechnology , Molecular Biology
Politics, finance, science
Content
In Vitro Gene Therapy Using Human iPS-Derived Mesoangioblast-Like Cells (HIDEMs) Combined with Microdystrophin (μDys) Expression as the New Strategy for Duchenne Muscular Dystrophy (DMD) Experimental Treatment
By Marta Budzinska, Agnieszka Zimna, Maciej Kurpisz, Agnieszka Malcher| MDPI@ All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Multi-omic analyses reveal a differential contribution of chromatin-associated PP1 holoenzymes to mitotic exit and G1 re-establishment.
By Konstantinos Stamatiou, Florentin Huguet, Marta Budzinska, Ines J deCastro| bioRxiv@ AbstractMitotic exit is an important part of the cell cycle that requires coordination of many chromatin and cytoskeleton remodelling events to successfully complete cell division and maintain cell identity. Protein de-phosphorylation is a key step in directing mitotic exit and Protein phosphatase (PP1) is essential to this process, however, the specific contribution of its numerous targeting subunits is still unknown.
In Vitro Gene Therapy Using Human iPS-Derived Mesoangioblast-Like Cells (HIDEMs) Combined with Microdystrophin (μDys) Expression as the New Strategy for Duchenne Muscular Dystrophy (DMD) Experimental Treatment
By Marta Budzinska, Agnieszka Zimna, Maciej Kurpisz, Agnieszka Malcher| MDPI@ All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Company Info
Avalere Health
Avalere is a healthcare consulting and advisory firm based in Washington, D.C. It specializes in strategy, policy, and data analysis for various sectors, including life sciences, health plans, providers, government agencies, and industry associations. As a subsidiary of Avalere Health, which acquired it in June 2022, Avalere focuses on providing data-driven insights and strategic guidance to address complex healthcare challenges. The firm offers a range of services, including market access and reimbursement strategies, policy analysis, due diligence for mergers and acquisitions, health economics and outcomes research, and implementation science. Avalere also utilizes proprietary data analytics tools to deliver insights, such as market sizing analyses and real-world evidence frameworks. Its clients include pharmaceutical and biotech companies, health plans, private equity firms, and government agencies, all seeking to navigate the healthcare landscape effectively.
'+1 202-207-1300
Founded: 2000